A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eligible age
18+ yrs
Accepts
Women
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
- ✓ Have a diagnosis of stress urinary incontinence
You may not qualify if…
- ✕ Have had urinary incontinence surgery
- ✕ Have recently received onabotulinumtoxin A (Botox) bladder injections or currently taking medications for urinary incontinence
- ✕ Have given birth within one year of screening
- ✕ Have had a change in body weight of more than 11 pounds within 90 days prior to screening
- ✕ Have used any anti-obesity medication or alternative weight loss remedies within 180 days prior to screening
- ✕ Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- ✕ Have had a cardiovascular health condition within 90 days prior to screening
- ✕ Are pregnant, intending to be pregnant, breastfeeding, or intending to breastfeed for the duration of the study
Where it's recruiting
Birmingham · Mobile
Mesa
Los Angeles · Montebello · Tustin
Lakewood
Fort Myers · Lake Worth · Miami · Panama City
Lawrenceville
Troy
Erie · Philadelphia
Houston
Newport News · Virginia Beach
Bellevue · Seattle
Source: ClinicalTrials.gov · NCT07202884 · last updated 2026-08-06